Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial. (2022)
Attributed to:
Evaluating new healthcare technologies in cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/jncics/pkac043
PubMed Identifier: 35877084
Publication URI: http://europepmc.org/abstract/MED/35877084
Type: Journal Article/Review
Volume: 6
Parent Publication: JNCI cancer spectrum
Issue: 4
ISSN: 2515-5091